Related Experiment Videos
Increasing effectiveness of interferon-alpha for malignancies
D J Lindner1, D V Kalvakolanu, E C Borden
1Department of Microbiology/Immunology, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore 21201, USA.
Abstract:
Alpha-interferons (IFN-alphas) have been shown to be effective agents in inducing the regression of various malignancies, including leukemias and lymphomas as well as solid tumors, and are the first human therapeutic proteins to result in increased survival in cancer patients. Based on their pleiotropic activities, IFNs have the potential for interacting synergistically with other anticancer agents. For example, preclinical in vitro and animal data suggest a synergistic antitumor interaction between IFN-alpha2 and the antiestrogens toremifene and tamoxifen. Further studies are required to elucidate the molecular basis for such synergistic interactions, particularly with respect to IFN-stimulated genes.
Insights
Alpha-interferons (IFN-alphas) show effectiveness in treating cancers and improving survival. Preclinical data suggest synergistic effects between IFN-alpha2 and antiestrogens like toremifene and tamoxifen against tumors.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Alpha-interferons (IFN-alphas) are effective in treating various cancers, including leukemias, lymphomas, and solid tumors.
- IFN-alphas are the first therapeutic proteins to demonstrate increased survival in cancer patients.
- Interferons possess pleiotropic activities, suggesting potential synergistic interactions with other anticancer agents.
Purpose of the Study:
- To explore the potential synergistic antitumor interactions between IFN-alpha2 and antiestrogens.
- To investigate the molecular basis of synergistic interactions between interferons and antiestrogens.
- To identify the role of IFN-stimulated genes in mediating synergistic anticancer effects.
Main Methods:
- Preclinical in vitro studies.
- Animal model studies.
- Analysis of IFN-stimulated genes.
Main Results:
- Preclinical data indicate a synergistic antitumor interaction between IFN-alpha2 and the antiestrogens toremifene and tamoxifen.
- Evidence suggests that interferons can enhance the efficacy of antiestrogen therapies.
Conclusions:
- IFN-alpha2 in combination with toremifene or tamoxifen demonstrates synergistic antitumor activity.
- Further research is needed to fully understand the molecular mechanisms underlying these synergistic interactions, particularly the role of IFN-stimulated genes.